Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joseph Haas

Joseph Haas is a senior writer for Informa’s pharmaceutical news publications, with more than eight years covering the biopharmaceutical industry. He previously worked in public affairs for a real estate trade association and wrote about housing and real estate before moving into healthcare. Most recently, he was managing editor of a newsletter publisher, leading its coverage of the implementation of the Medicare Part D prescription drug benefit. Joe’s areas of expertise include business development, mergers and acquisitions, infectious diseases and liver diseases, including hepatitis C, hepatitis B and non-alcoholic steatohepatitis (NASH). He edits the popular Deal Watch column and enjoys profiling start-up companies. 

Writes for:

Latest From Joseph Haas

AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials

Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.

Sales & Earnings Business Strategies

Trulicity Takes Hit From Payer Mix, But Lilly Emerges From Q3 Ahead

US pricing for Trulicity due to payer mix fluctuations dragged down solid volume growth. Lilly hopes revenue from COVID-19 therapies will help it hit annual guidance, but bamlanivimab failed to benefit hospitalized patients.

Sales & Earnings Business Strategies

Bayer’s Finerenone Shows Renal, CV Benefits In CKD/Type 2 Diabetes Patients – But Is It Enough?

Study shows risk reduction in both renal failure and cardiovascular events, but analysts question competitiveness versus SGLT-2 inhibitors and safety compared to earlier MR antagonists.

Clinical Trials Business Strategies

Retrophin Bolsters Portfolio With Orphan Technologies Buyout

The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.

Deals M & A

With Lumasiran Pediatric Data, Alnylam Hopes For Approvals In All PH1 Patients

Alnylam shows that lumasiran offers similar safety and efficacy in primary hyperoxaluria type 1 patients who are six or younger as it does in older patients. US and EU regulatory decisions loom.

Clinical Trials Rare Diseases

InCarda Gets $30m Closer To Inhalable AF Drug/Device Therapy

The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.

Financing Research and Development Strategies
See All
UsernamePublicRestriction

Register